Calidi Biotherapeutics (CLDI) Competitors $1.57 +0.12 (+8.28%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.05 (-3.12%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. NEUP, CLSD, SYBX, APLM, FNCH, LSTA, RVPH, TAOX, IXHL, and CINGShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Neuphoria Therapeutics (NEUP), Clearside Biomedical (CLSD), Synlogic (SYBX), Apollomics (APLM), Finch Therapeutics Group (FNCH), Lisata Therapeutics (LSTA), Reviva Pharmaceuticals (RVPH), Synaptogenix (TAOX), Incannex Healthcare (IXHL), and Cingulate (CING). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Neuphoria Therapeutics Clearside Biomedical Synlogic Apollomics Finch Therapeutics Group Lisata Therapeutics Reviva Pharmaceuticals Synaptogenix Incannex Healthcare Cingulate Calidi Biotherapeutics (NYSE:CLDI) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment. Do institutionals and insiders hold more shares of CLDI or NEUP? 12.5% of Calidi Biotherapeutics shares are held by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are held by institutional investors. 6.7% of Calidi Biotherapeutics shares are held by insiders. Comparatively, 0.7% of Neuphoria Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer CLDI or NEUP? In the previous week, Neuphoria Therapeutics had 2 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 2 mentions for Neuphoria Therapeutics and 0 mentions for Calidi Biotherapeutics. Neuphoria Therapeutics' average media sentiment score of 0.95 beat Calidi Biotherapeutics' score of 0.00 indicating that Neuphoria Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calidi Biotherapeutics Neutral Neuphoria Therapeutics Positive Which has more volatility & risk, CLDI or NEUP? Calidi Biotherapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Do analysts recommend CLDI or NEUP? Neuphoria Therapeutics has a consensus price target of $28.00, indicating a potential upside of 127.46%. Given Neuphoria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Neuphoria Therapeutics is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Neuphoria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CLDI or NEUP more profitable? Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Neuphoria Therapeutics N/A N/A N/A Which has better earnings & valuation, CLDI or NEUP? Neuphoria Therapeutics has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/ANeuphoria Therapeutics$10K2,314.28-$15.49MN/AN/A SummaryNeuphoria Therapeutics beats Calidi Biotherapeutics on 9 of the 11 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.38M$295.89M$5.67B$21.54BDividend YieldN/AN/A5.75%3.52%P/E RatioN/AN/A75.7529.48Price / SalesN/A451.53561.4160.08Price / CashN/A22.4437.6024.33Price / Book-0.6810.2212.394.57Net Income-$29.22M-$111.61M$3.29B$1.00B7 Day Performance1.95%1.01%1.27%-0.20%1 Month Performance-7.65%7.07%3.84%2.42%1 Year Performance-89.14%-12.02%60.97%13.12% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.2155 of 5 stars$1.57+8.3%N/A-89.6%$5.38MN/A0.0038Gap DownNEUPNeuphoria Therapeutics2.3584 of 5 stars$11.45+3.7%$28.00+144.5%N/A$20.75M$10K0.00N/AUpcoming EarningsGap UpCLSDClearside Biomedical2.4542 of 5 stars$4.00+1.0%$63.00+1,475.0%-77.8%$20.74M$1.66M-0.7230Gap UpSYBXSynlogic1.6077 of 5 stars$1.71-2.0%N/A+9.9%$20.36MN/A-21.3180Positive NewsAPLMApollomics0.5768 of 5 stars$18.43+51.3%N/A+35.5%$20.34M$1.49M0.0045Positive NewsGap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.52+2.6%N/A+14.4%$20.11MN/A-1.42190High Trading VolumeLSTALisata Therapeutics3.2596 of 5 stars$2.35+2.6%$23.50+900.0%-17.1%$20.05M$1M-1.0530Positive NewsRVPHReviva Pharmaceuticals3.1487 of 5 stars$0.29+2.5%$5.33+1,712.2%-77.1%$19.90MN/A-0.455TAOXSynaptogenix0.1331 of 5 stars$5.96+4.7%N/AN/A$19.84MN/A-0.304IXHLIncannex Healthcare0.425 of 5 stars$0.61-8.9%N/A-70.5%$19.77M$10K-0.513Positive NewsUpcoming EarningsCINGCingulate2.421 of 5 stars$3.83+4.9%$26.25+585.4%-26.4%$19.76MN/A-0.9320 Related Companies and Tools Related Companies Neuphoria Therapeutics Competitors Clearside Biomedical Competitors Synlogic Competitors Apollomics Competitors Finch Therapeutics Group Competitors Lisata Therapeutics Competitors Reviva Pharmaceuticals Competitors Synaptogenix Competitors Incannex Healthcare Competitors Cingulate Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLDI Stock Alerts